ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
34.65
-0.26%
US Tech 100
19,220.40
0.28%
S&P 500
5,431.60
-0.04%
US Dollar vs CAD
1.37422
-0.07%
Bitcoin
66,184.97
-0.68%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. Organon and Co (OGN)

  7. Organon and Co (OGN) News

OGN

Organon (OGN)

Organon and Co
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:OGN
DateTimeSourceHeadlineSymbolCompany
06/11/20242:17PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
06/11/20242:16PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
06/11/20242:16PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
06/06/20246:00AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:OGNOrganon and Co
05/24/202412:59PMBusiness WireEuropäische Arzneimittel-Agentur (EMA) validiert Einreichungen von Henlius und Organon für den Prolia ® und Xgeva ® (Denosumab) Biosimilar-Kandidaten HLX14NYSE:OGNOrganon and Co
05/24/202412:59PMBusiness WireL’Agence européenne des médicaments (EMA) entérine les dépôts de Henlius et d’Organon pour le candidat biosimilaire HLX14 de Prolia ® et Xgeva ® (denosumab)NYSE:OGNOrganon and Co
05/24/202410:29AMBusiness Wire欧州医薬品庁（EMA）、ヘンリウスとオルガノンによるProlia ® およびXgeva ® （デノスマブ）バイオシミラー候補HLX14を認証NYSE:OGNOrganon and Co
05/24/20245:00AMBusiness WireEuropean Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14NYSE:OGNOrganon and Co
05/17/20243:15PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:OGNOrganon and Co
05/07/20247:20PMBusiness WireOrganon Announces Pricing of $1.0 Billion Senior Notes OfferingNYSE:OGNOrganon and Co
05/07/20243:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
05/07/20243:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
05/07/20243:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
05/07/20243:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
05/07/20243:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
05/07/20243:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
05/07/20243:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
05/07/20246:58AMBusiness WireOrganon Announces Proposed $1.0 Billion Senior Notes OfferingNYSE:OGNOrganon and Co
05/02/20246:30AMBusiness WireOrganon Reports Results for the First Quarter Ended March 31, 2024NYSE:OGNOrganon and Co
04/09/20247:13AMBusiness WireProlia ® とXgeva ® （デノスマブ）との第3相比較臨床試験でバイオシミラー候補HLX1​​4が主要評価項目を達成NYSE:OGNOrganon and Co
04/08/20241:31PMBusiness WireKlinische Phase-3-Vergleichsstudie zwischen Prolia ® und Xgeva ® (Denosumab) - Biosimilar-Kandidat HLX14 erreicht primäre EndpunkteNYSE:OGNOrganon and Co
04/08/20241:31PMBusiness WireL'essai clinique comparatif de phase 3 du candidat biosimilaire de Prolia ® et de Xgeva ® (denosumab) HLX14 remplit les critères d'évaluation primairesNYSE:OGNOrganon and Co
04/08/20245:15AMBusiness WireOrganon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024NYSE:OGNOrganon and Co
04/08/20245:00AMBusiness WirePhase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary EndpointsNYSE:OGNOrganon and Co
03/08/20248:01AMPR Newswire (Canada)On International Women's Day, Organon Canada is encouraging businesses to Invest in HER and help address gender inequities through women's healthNYSE:OGNOrganon and Co
03/08/20248:01AMPR Newswire (Canada)À l'occasion de la Journée internationale des femmes, Organon Canada encourage les entreprises à Investir en elle et à lutter contre les inégalités entre les genres par la santé des femmesNYSE:OGNOrganon and Co
03/01/20243:24PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
03/01/20243:24PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
03/01/20243:22PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
03/01/20243:22PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
 Showing the most relevant articles for your search:NYSE:OGN

Your Recent History

BIT
S29671
Societe Generale Effekten
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved